Walleye Capital
SABS icon

Walleye Capital’s SAB Biotherapeutics SABS Stock Holding History

Walleye Capital’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,995
Closed -$201 – 2287
2021
Q3 		$201 Sell
1,995
-5,798
-74% -$578K 0.01% 1189
2021
Q2 		$776 Buy
+7,793
New +$773K 0.03% 550

Other funds holding SABS

FPB
First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
IFAM
Institutional & Family Asset Management Fort Collins, Colorado $654M AUM 12.29% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 21.71% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
V
Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return

Walleye Capital's SABS Position: Q4 2021 in Review

Walleye Capital sold out of SAB Biotherapeutics (SABS) in Q4 2021, closing a stake of 1,995 shares — an estimated $201 sold.

Walleye Capital first reported a position in SABS in Q2 2021 and held it in 2 quarters. The position peaked at $776 in Q2 2021. 34 funds tracked by Wall St. Rank hold SABS as of Q4 2021.

  • Walleye Capital reported no remaining SAB Biotherapeutics position as of Q4 2021 after selling out during the quarter.
  • Walleye Capital sold 1,995 SAB Biotherapeutics shares in Q4 2021, an estimated $201.
  • Walleye Capital first reported a position in SAB Biotherapeutics in Q2 2021 and held it in 2 quarters.
  • Walleye Capital's SAB Biotherapeutics position peaked at $776 in Q2 2021.
  • 34 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q4 2021.

Based on Walleye Capital's 13F filing for Q4 2021, filed 3 Mar 2022.